• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in cases of esophageal cancer.

作者信息

Katano K, Tsujitani S, Maeta M, Fukuda K, Oka S, Hisamitsu K, Ikeguchi M, Kaibara N

机构信息

Department of Surgery I, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.

出版信息

Oncol Rep. 2001 May-Jun;8(3):605-9.

PMID:11295088
Abstract

Intraoperative intrapleural (i.pl.) cisplatin (CDDP) treatment during thoracotomy was performed for esophageal cancers. Three patients underwent isotonic (308 mOsm/l) CDDP treatment. Hypotonic CDDP treatments with a 154 mOsm/l solution and a 62 mOsm/l solution were administered to 4 and 9 patients, respectively. The maximum concentrations (Cmax) of both total and filterable platinum in the plasma after injection of the hypotonic solution were significantly higher than those after injection of the isotonic solution. The area under the curve of concentration versus time (AUC) of the plasma of the 62 mOsm/l solution was significantly higher than that of the 154 mOsm/l and isotonic solution. Although higher levels of the Cmax may increase side-effects, the hypotonic condition of the i.pl. fluid and increased AUC in the plasma may escalate the accumulation of platinum in i.pl. cancer cells. These results suggest that hypotonic i.pl. CDDP is tolerable and may be useful for treatment of the incipient phase of pleural carcinomatosis and for prophylaxis of postoperative recurrence.

摘要

相似文献

1
Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in cases of esophageal cancer.
Oncol Rep. 2001 May-Jun;8(3):605-9.
2
Hypotonic intrapleural cisplatin chemotherapy as treatment for pleural carcinomatosis in an experimental model.低渗性胸腔内顺铂化疗作为实验模型中胸膜转移瘤的治疗方法。
Anticancer Res. 1997 Nov-Dec;17(6D):4547-52.
3
Pharmacokinetics of hypotonic cisplatin chemotherapy administered into the peritoneal and the pleural cavities in experimental model.实验模型中腹腔和胸腔内注射低渗顺铂化疗的药代动力学
Anticancer Res. 2000 May-Jun;20(3A):1603-7.
4
Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats.对于大鼠腹膜癌,在低渗溶液中给药优于腹腔内顺铂化疗时增加剂量。
Oncology. 1999 Jul;57(1):77-82. doi: 10.1159/000012004.
5
Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study.
J Exp Clin Cancer Res. 2001 Jun;20(2):183-8.
6
Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.基于药代动力学分析的卵巢癌患者术中腹腔内顺铂暴露情况的改善。
Cancer Chemother Pharmacol. 2008 Mar;61(3):415-21. doi: 10.1007/s00280-007-0484-x. Epub 2007 May 15.
7
Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.司他铂(JM216)的药代动力学,这是一种口服铂(IV)配合物,每日口服给药5天或14天。
Anticancer Res. 2003 May-Jun;23(3C):2757-65.
8
Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.顺二氨二氯铂(II)低剂量和高剂量输注的药代动力学
J Surg Oncol. 1996 Jun;62(2):135-8. doi: 10.1002/(SICI)1096-9098(199606)62:2<135::AID-JSO10>3.0.CO;2-7.
9
Hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in patients with lung cancer. In vitro experiments and preliminary clinical results.肺癌患者开胸手术时发现的癌性胸膜炎的低渗顺铂治疗。体外实验及初步临床结果。
J Thorac Cardiovasc Surg. 1993 Jun;105(6):1041-6.
10
Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.新型化学保护剂BNP7787和顺铂及其代谢产物的药代动力学和初步临床数据。
Clin Pharmacol Ther. 2003 Aug;74(2):157-69. doi: 10.1016/S0009-9236(03)00150-4.

引用本文的文献

1
Regulation of osmolality for cancer treatment.癌症治疗中的渗透压调节。
J Physiol Sci. 2017 May;67(3):353-360. doi: 10.1007/s12576-017-0528-x. Epub 2017 Feb 10.